Search

Displaying results 1691 - 1700 of 8468 in total
  1. Drug

    Bitolterol

    go.drugbank.com/drugs/DB00901
    ApprovedWithdrawn

    Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.

  2. Drug

    Sodium phosphate, monobasic, unspecified form

    go.drugbank.com/drugs/DB14503
    Approved

    Mixtures: Reveos Select CPD with AS-5 Red Cell Preservative Solution For Collection Of 500ml Of Blood, TERUFLEX Blood Bag System with Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative
  3. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    [A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. … [T210] Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine.

  4. Target

    Plasminogen activator inhibitor 2

    go.drugbank.com/bio_entities/BE0000969
    TargetHumans

    The monocyte derived PAI-2 is distinct from the endothelial cell-derived PAI-1

    Synonyms: PAI-2
  5. Drug

    Protein C

    go.drugbank.com/drugs/DB11312
    ApprovedInvestigational

    Once in its activated form, APC functions as a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. … Protein C is available in concentrated form as the product Ceprotin, which is indicated for use in pediatric and adult patients with severe congenital protein C deficiency for the prevention and treatment

  6. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    It was developed by Novartis and was granted FDA approval on November 15, 2019. … [T734] Currently, patients are prescribed [hydroxyurea] to raise levels of fetal hemoglobin as a method of reducing morbidity and mortality.

  7. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    Teslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012. … The contrast agent is present as mangafodipir trisodium marketed under the name Teslascan.

  8. Drug

    Butabarbital

    go.drugbank.com/drugs/DB00237
    ApprovedIllicitWithdrawn

    [A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.[L13613] … [A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines.

  9. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    acts as a highly selective potassium removing agent. … [L2933] The treatment effect was maintained for up to 12 months.[L2933]

  10. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    It was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries. … Most recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953]